News Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Jun 15, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jun 11, 2021Third milestone payment related to the development of Oral KORSUVA™
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...
- Jun 07, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- May 17, 2021Conference Call and Live Audio Webcast Scheduled for Tuesday, May 18, 2021 at 10:00 a.m. ET
Corporate Updates YTD SWK has closed two financings totaling up to $14.0 million Enteris BioPharma subsidiary announced completion of manufacturing facility expansion and launch of CDMO business...
- May 17, 2021
The Board of Directors (the "Board") of SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") and its controlling stockholder, funds affiliated with Carlson Capital, L.P. ("Carlson"),...
- May 03, 2021CDMO Business Driven by Custom Solutions from Bench to Market for the Development and Manufacture of Difficult to Formulate Drugs and Highly Potent Compounds
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Apr 06, 2021
SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") confirmed that on April 5, 2021, a Special Committee (the "Special Committee") of the Company's Board of Directors received a...
- Mar 31, 2021Specialty Finance Portfolio Growth, Underlying Credit Performance Highlight Strong 2020
Corporate Highlights Closed four transactions in 2020 deploying $34.8 million; additional $8.1 million deployed to existing borrowers Income producing assets as of December 31, 2020 reached an...
- Mar 24, 2021
Sincerus Pharmaceuticals, the parent company of Prescriber's Choice and Sincerus Florida, today announced the completion of a major new round of growth financing with SWK Holdings Corporation (Nasdaq:
- Mar 16, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...